North America, Europe, and Asia-Pacific Large Molecule Bioanalysis Testing Services Market Research Report Forecast to 2030
The market for large molecule bioanalysis testing services in North America, Europe, and Asia-Pacific is expanding due to rising demand for high-tech and dependable large molecule bioanalytical testing services, a growing trend of outsourcing laboratory testing services, and an increase in the number of clinical trials. However, the difficulties in developing appropriate analytical techniques are limiting the growth of the North America, Europe, and Asia-Pacific large molecule bioanalysis testing services market. Furthermore, the growing prevalence of chronic diseases is expected to provide lucrative growth opportunities for the North America, Europe, and Asia-Pacific large molecule bioanalysis testing services market.
The concentration of large molecules in biological samples such as proteins and antibodies are determined using large molecule bioanalytical testing services. Large molecules are frequently utilized in drug development, and bioanalytical testing is required to ensure these drugs' safety and efficacy.
The expected growth in market can be attributed to the increasing demand for high-tech and reliable large molecule bioanalytical testing services, growing trend of outsourcing laboratory testing services, and rising R&D expenditure in the biopharmaceutical sector. However, the market is also held back by challenges in the development of proper analytical techniques. Nevertheless, it is anticipated that the growing incidence of chronic diseases will create lucrative opportunities for the players operating in the North America, Europe, And Asia-Pacific large molecule bioanalysis testing services market.
MARKET SEGMENTATIONBased on test type, the large molecule bioanalysis testing market has been segmented into pharmacokinetic (PK) studies, pharmacodynamic studies, bioequivalence studies, immunogenicity testing, biomarker testing and others.
Based on therapeutic area, the market has been segmented into oncology, infectious diseases, cardiovascular diseases, neurology, autoimmune disorders, and others.
Based on test type, the market has been segmented into pharmaceutical and biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), contract research organizations (CROs), academic and research institutes, and others.
Regional AnalysisBased on region, the large molecule bioanalysis testing services market has been segmented into North America, Europe, and Asia-Pacific. North America accounted for the largest market share of 45.29% in 2022 and is anticipated to reach approximately USD 1,498.85 million by 2030 at an 8.70% CAGR during the forecast period. However, Asia-Pacific is projected to register the highest CAGR of 11.52% by 2030.
MAJOR PLAYERSAmerica Holdings (US), ICON plc (Ireland), SGS Société Générale de Surveillance SA (Switzerland), WuXi AppTec (China), Charles River Laboratories (US), Eurofins Scientific (luxembourg), QPS Holdings (US), BioTechne (US), PPD, Inc (US), BioAgilytix Labs (US), Smithers (US), Meso Scale Diagnostic, LLC (US), and CMIC HOLDINGS CO., LTD (Japan).
Companies MentionedAmerica Holdings (US)
ICON plc (Ireland)
SGS Société Générale de Surveillance SA (Switzerland)
WuXi AppTec (China)
Charles River Laboratories (US)
Eurofins Scientific (luxembourg)
QPS Holdings (US)
BioTechne (US)
PPD
Inc (US)
BioAgilytix Labs (US)
Smithers (US)
Meso Scale Diagnostic
LLC (US)
and CMIC HOLDINGS CO.
LTD (Japan)